Lung (includes NSCLC, SCLC, Mesothelioma)

It's Never Too Late To Quit Smoking Before Lung Surgery

(Reuters Health) Jan 15, 2019 - Smokers who’ll be having surgery for lung cancer should quit smoking before the operation, and the sooner the better, a new study shows.

read article

Complication Rates And Costs Of Invasive Lung Cancer Diagnostic Tests May Be Higher Than Anticipated

(MD Anderson) Jan 14, 2019 - Complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials, and associated downstream costs ranged from $6,320 to $56,845 on average, according to a new study. The researchers believe the findings, published today in JAMA Internal Medicine, reinforce the need for including these risks in the shared decision-making communication between patients and physicians when considering lung cancer screening for high-risk individuals. Lung cancer is the second most common cancer in both men and women, and the leading cause of cancer death in the U.S. As most patients with lung cancer are diagnosed at advanced stages, effective early screening strategies for lung cancer are a major public health priority, explained Ya Chen Tina Shih, Ph.D., professor of Health Services Research and corresponding author on the study.

read press release

Heat Biologics Doses First Patient in New Cohort of its Expanded Phase 2 Trial of HS-110 in Combination with Merck's KEYTRUDA(R) in Non-Small Cell Lung Cancer Trial

(Digital Journal) Jan 14, 2019 - Phase 2 expansion into first line maintenance therapy follows positive interim results reported in 2018 in combination with Bristol-Myers' Opdivo® (Nivolumab).

read article

What Happens When The Doctor Blames You For Your Own Cancer?

(Washington Post) Jan 11, 2019 - How bias in the medical community hurts lung cancer patients.

read article (free registration required)

Bio-Thera Solutions Ltd Partners with Cipla Ltd to Market Key Cancer Biosimilar

(MarketWatch) Jan 14, 2019 - Bio-Thera Solutions Ltd announced today that it has reached a licensing agreement with Cipla Limited for BAT1706, its bevacizumab biosimilar, under which Cipla will have exclusive rights to distribute and market the drug in select emerging markets.

read article

Heat Biologics Expands Mid-Stage Study Of HS-110 To Include Different PD-1 Inhibitor

(Seeking Alpha) Jan 10, 2019 - Heat Biologics says it has expanded its Phase 2 clinical trial evaluating HS-110 combo therapies in patients with non-small cell lung cancer to include another PD-1 inhibitor (Bristol-Myers Squibb's Opdivo and Merck's Keytruda are already involved) to treat patients at an earlier stage in their cancer.

read article

A Journey With Lung Cancer

(Wall Street Journal) Jan 8, 2019 - Twelve years—and a world of difference—between bouts for one patient and her family.

read article (paid subscription required)

Corvus Announces Enrollment in Second Arm of Phase 1/1b Dose-Escalation Trial of Anti-CD73 Antibody, CPI-006, Focused on Combination with CPI-444 Adenosine Antagonist

(Markets Insider) Jan 8, 2019 - Corvus Pharmaceuticals, Inc. today announced that it has initiated patient enrollment in the second arm of its ongoing Phase 1/1b dose-escalation study. This arm is evaluating CPI-006, a humanized monoclonal antibody directed against CD73, in combination with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor.

read article

Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews

(MarketWatch) Jan 7, 2019 - Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that the Safety Review Committee (SRC) has endorsed dose escalation in the ongoing ADP-A2AFP (AFP) study in patients with hepatocellular carcinoma (liver cancer) to the second dose cohort.

read article

Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)

(The Business Journals) Jan 7, 2019 - Mirati Therapeutics, Inc. today announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO®), in Mirati's planned Phase 3 trial in second line non-small cell lung cancer (NSCLC) patients who have progressed following treatment with a platinum-based regimen and a checkpoint inhibitor.

read article

To Screen Or Not To Screen? That Is The Question

(UCCC/Colorado Cancer Blogs) Jan 3, 2019 - If more and more younger people, or different demographics of people, are being diagnosed with colon cancer and lung cancer, do the old screening guidelines still hold up?

read article

Merck’s KEYTRUDA® (pembrolizumab) Receives Five New Approvals in Japan, Including in Advanced Non-Small Cell Lung Cancer (NSCLC), as Adjuvant Therapy for Melanoma, and in Advanced Microsatellite Instability-High (MSI-H) Tumors

(Merck) Jan 3, 2019 - Merck, known as MSD outside the United States and Canada, announced today that KEYTRUDA, Merck’s anti-PD-1 therapy, has simultaneously received five new approvals from the Japan Pharmaceuticals and Medical Devices Agency (PMDA), including three expanded uses in advanced non-small lung cancer (NSCLC), one in melanoma, as well as a new indication in advanced microsatellite instability-high (MSI-H) tumors. The following new approvals were all granted priority review by the PMDA: KEYTRUDA in combination with pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the first-line treatment of unresectable, advanced/recurrent nonsquamous NSCLC regardless of PD-L1 expression (based on results of the Phase 3 trial KEYNOTE-189); KEYTRUDA in combination with carboplatin and paclitaxel or nab-paclitaxel for the first-line treatment of unresectable, advanced/recurrent squamous NSCLC regardless of PD-L1 expression (based on results of the Phase 3 trial KEYNOTE-407); KEYTRUDA monotherapy in the first-line treatment of PD-L1-positive (Tumor Proportion Score [TPS] ≥1%) unresectable, advanced/recurrent NSCLC (based on results of the Phase 3 trial KEYNOTE-042);

read corporate press release

Merck's Keytruda Wins 5 New Approvals In Japan

(MarketWatch) Jan 3, 2019 - Merck & Co. Inc. said Thursday it has received five new approvals from the Japanese regulator for its Keytruda treatment, including three expanded uses in advanced non-small lung cancer, one in melanoma and a new indication in advanced microsatellite instability-high (MSI-H) tumors. Keytruda was first approved in Japan two years ago, according to Jannie Oosthuizen, managing director of Merck, which is known as MSD in overseas markets, in Japan. Cancer is the leading cause of death in Japan and lung cancer is second most commonly diagnosed cancer, after colorectal cancer. Merck shares were down 2.1% premarket, but have gained 36% in the last 12 months, while the S&P 500 has fallen 7.5%.

read article

Spectrum Pharmaceuticals Announces Full Enrollment of the Poziotinib EGFR Cohort for Previously Treated Non-Small Cell Lung Cancer Patients with Exon 20 Insertion Mutations

(The Business Journals) Jan 2, 2019 - Spectrum Pharmaceuticals, Inc. today announced full enrollment of cohort 1 (N=87) for previously treated Non-Small Cell Lung Cancer (NSCLC) patients with EGFR exon 20 insertion mutations with sites across the U.S., Europe, and Canada.

read article

Veracyte Announces Strategic Collaboration with Johnson & Johnson Innovation in Battle Against Lung Cancer

(Digital Journal) Jan 3, 2019 - Veracyte, Inc. announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable.

read article

Personal Genome Diagnostics Collaborates with Merck on Global Clinical Trial Evaluating Response to Dual Biomarker Directed Precision Oncology Combination Therapy

(MarketWatch) Jan 3, 2019 - Personal Genome Diagnostics Inc. today reported that its 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (NSCLC) (KEYNOTE-495).

read article

With The Right Care, Patients Now Living A Median 6.8 Years After Stage IV ALK+ Lung Cancer Diagnosis

(UCCC/Colorado Cancer Blogs) Dec 31, 2018 - According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chance of being alive 5 years later.

read article

Merck Provides Update on KEYTRUDA® (pembrolizumab) Supplemental Biologics License Application (sBLA) for KEYNOTE-042 Trial

(Merck) Dec 20, 2018 - Merck today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) without EGFR or ALK genomic tumor aberrations. The sBLA is based on results of the Phase 3 KEYNOTE-042 trial where KEYTRUDA monotherapy demonstrated a significant improvement in overall survival compared with chemotherapy in this patient population. The company recently submitted additional data and analyses to the FDA, which constitutes a major amendment and extends the Prescription Drug User Fee Act (PDUFA), or target action date, by three months to April 11, 2019. Merck continues to work closely with the FDA during the review of this sBLA.

read corporate press release

G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer

(G1 Therapeutics) Dec 19, 2018 - Achieved both primary endpoints: statistically significant reductions in the duration and occurrence of Grade 4 neutropenia.

read corporate press release

Spectrum Pharmaceuticals Provides Poziotinib Update

(Spectrum) Dec 19, 2018 - Spectrum Pharmaceuticals, Inc., today announced that based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S. Food and Drug Administration (FDA) did not grant Breakthrough Therapy Designation (BTD) to poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations.

read corporate press release
Next Page